Ambrosia launches revolutionary “Direct-to-Apple Watch” NightRider BluCon for Continuous Glucose Monitoring

SAN FRANCISCO, July 19, 2019 /PRNewswire/ — Ambrosia Systems, a fast growing medical  technology company, today announced the launch of the next version of NightRider BluCon. The new NightRider BluCon works with Apple watch to display glucose readings from the FreeStyle Libre and Libre Pro sensors on Apple watch without the phone. This will help parents of the millions of Type 1 diabetic children monitor their children’s glucose levels when the child is away. Currently, parents don’t have a way to know the current glucose levels of their Type 1 diabetic child if he or she is not carrying their phone, which most schools don’t allow. Also, it is difficult for young children to carry their phone all the time.

After the initial setup of Ambrosia’s NightRider and LinkBluCon app on the iPhone, the user can change the mode to Apple Watch on LinkBluCon’s settings screen, this will switch the NightRider connection from the iPhone to Apple Watch and will start displaying glucose readings on Apple Watch without the phone. If Apple Watch has a cellular connection, parents can install Ambrosia’s FollowBluCon app on their phone and, after setup, will be able to see glucose readings updates of their child every five minutes.

Disclaimer:

Ambrosia apps are not FDA approved and should not be used to make medical decisions.
FreeStyle Libre is a trademark of Abbott Diabetes Care Inc. Ambrosia Systems Inc. does not have any kind of relationship with Abbott Diabetic Care or Abbott Laboratories.

About Ambrosia Systems

Ambrosia Systems is a fast growing medical technology company focused on building easy to use and affordable technology solutions for patients, providers, payers and caregivers. The NightRider BluCon is currently in use in more than 100 countries with FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre Pro sensors. To learn more, visit www.ambrosiasys.com

Media Contacts: Mia Flaherty, Ambrosia Systems Inc. mia.flaherty@ambrosiasys.com, +1-415-293-8242

View original content to download multimedia:http://www.prnewswire.com/news-releases/ambrosia-launches-revolutionary-direct-to-apple-watch-nightrider-blucon-for-continuous-glucose-monitoring-300887904.html

SOURCE Ambrosia Systems

Staff

Recent Posts

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

10 seconds ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

3 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

3 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

3 minutes ago